We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Research Grant, Patent Grant & Directorate Change

28 May 2010 07:00

RNS Number : 6897M
Byotrol PLC
28 May 2010
 



 

 

28 May 2010

 

 

Byotrol plc

 

Award of Research Grant, Enhanced Patent Grant

and

Directorate Change

 

Byotrol plc ('Byotrol' or 'the Company'), the leading AIM listed anti-microbial hygiene company, is pleased to announce that it has been awarded a research grant by North West Development Agency (NWDA) to assist in funding the development of an innovative bio-medical product. The NWDA grant, totalling £443,824, is to be paid over three years to develop, in particular, the range of applications in the Consumer Products division.

 

NWDA innovation grants are only awarded to proven technologies which have undergone rigorous testing.

 

In addition to the research grant announced above, the UK Patent Office has granted a further technology patent as of June 16th 2010 in favour of the Byotrol anti-microbial technology. This patent, which builds on the original international Byotrol patent protection, covers key ingredients responsible for the molecular structures that are now known to provide Byotrol with its leading edge anti-microbial residual efficacy. Granting of this patent extends the scope of the original patent and helps to build the Byotrol anti-microbial technology platform.

 

Byotrol also announces that, due to his taking up the Cabinet post of Secretary of State for the department of Work and Pensions in the Coalition Government, Iain Duncan Smith has resigned as a Director of the Company.

 

Mr Duncan Smith was not remunerated in his advisory role at Byotrol. The Board wishes him well in his new post and thanks him for his support and advice over the last twelve months.

 

Commenting on the award, Dr Gary Millar, CEO of Byotrol said:

 

"We are very excited and proud to have been awarded an exceptional R&D grant by the Northwest Regional Development Agency. The confidence of NWDA in both our technology and our ambition to develop new anti-microbial products aimed at the Healthcare, Foods and Consumer sectors is a significant endorsement.

 

"The grant will help Byotrol to grow its technical resources at our laboratory at Daresbury Science and Innovation Campus and build good science around anti-microbial technology in a challenging and very topical market."

 

 

 

Enquiries:

 

Byotrol plc 0161 277 9518

Gary Millar, Chief Executive

Richard Bell, Finance Director

 

Charles Stanley Securities 020 7149 6000

Nominated Adviser

Russell Cook / Carl Holmes

 

Winningtons 020 3043 4162

Tom Cooper / Paul Vann 0797 1221972

 

 

Notes to Editors:

 

Byotrol Plc (BYOT.L), quoted on AIM, is a leading microbial technology hygiene company, operating globally in the Health, Food, Leisure, Consumer, Industrial and Agriculture sectors, providing a low toxicity product with a broad-based and long lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, microbacteria and algae.

 

The Byotrol product can be used as a stand alone product or as a complementary biocide additive to existing products to improve their performance in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company has prioritised the development of a technology that creates easier, safer and cleaner lives through partnering with providers of essential goods and services. Byotrol is the catalyst behind the aptly named global 'Hygiene Revolution'.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCARMFTMBITBPM
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.